Evidence map›Paper›PMID 41399344›Full record

ArticleGastro hep advances2025

Evette B M Hillman, Danielle Carson, Julian R F Walters, Martin Fritzsche, Ryan Mate, Katie E Chappell, Elena Chekmeneva, Maria Gomez Romero, Stephen J Lewis, Sjoerd Rijpkema and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Gastro hep advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Response to Kårhus et al. Regarding "Gastro hep advances · 2026
    Article
  2. Letter to the Editor Regarding "Gastro hep advances · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Evette B M HillmanDiagnostics, Medicines and Healthcare products Regulatory Agency, London, UK.
Danielle CarsonDiagnostics, Medicines and Healthcare products Regulatory Agency, London, UK.
Julian R F WaltersDivision of Digestive Diseases, Imperial College London, London, UK.
Martin FritzscheDiagnostics, Medicines and Healthcare products Regulatory Agency, London, UK.
Ryan MateDiagnostics, Medicines and Healthcare products Regulatory Agency, London, UK.
Katie E ChappellThe National Phenome Centre, Imperial College London, London, UK.
Elena ChekmenevaThe National Phenome Centre, Imperial College London, London, UK.
Maria Gomez RomeroThe National Phenome Centre, Imperial College London, London, UK.
Stephen J LewisDepartment of Gastroenterology, University Hospital Plymouth, Plymouth, UK.
Sjoerd RijpkemaDiagnostics, Medicines and Healthcare products Regulatory Agency, London, UK.
Elizabeth M H WellingtonSchool of Life Sciences, The University of Warwick, Coventry, UK.
Ramesh ArasaradnamDepartment of Gastroenterology, University Hospitals Coventry & Warwickshire, Coventry, UK.
Gregory C A AmosDiagnostics, Medicines and Healthcare products Regulatory Agency, London, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Aims: Bile acid diarrhea (BAD) is a common cause of frequent loose stools, urgency, and incontinence, which is under-recognized due to limited diagnostic test availability and unclear pathogenesis. This study aimed to investigate fecal changes in well-defined subjects. Methods: Fecal samples were compared in BAD patients (n = 26), diagnosed by SeHCAT testing, and healthy controls (n = 21). Shotgun metagenomic sequencing was used to identify microbiome species and functional genes. An extended set of 38 bile acids was quantified by liquid chromatography mass spectrometry, including various epimers and intermediates, such as iso- (3-beta-OH), oxo (keto), allo (5-alpha), and 3-sulfated forms. Results: Alpha diversity, reflecting microbial richness, was reduced in BAD patients with severe forms of the disease, while beta diversity demonstrated distinct microbial profiles between groups. Conclusion: BAD may result from an overgrowth of

Indexed as

Bile AcidsChronic DiarrheaIso-Bile AcidsMicrobiomeMucosal Biofilms

Identifiers

PMID41399344
PMCPMC12702444

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.